ArticleFrontiers in medicine2026
Vaginal microbiota and genitourinary syndrome of menopause in premenopausal breast cancer patients receiving endocrine therapy: a longitudinal cohort study protocol.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endocrine therapy with ovarian function suppression combined with aromatase inhibitors or tamoxifen is essential for hormone receptor-positive breast cancer in premenopausal women, but often induces genitourinary syndrome of menopause (GSM) via hypoestrogenism. Existing research focuses on natural menopause, with limited longitudinal data on vaginal microbiome changes in breast cancer survivors, especially amid rising cases among young Chinese women. Objectives: To (1) assess temporal effects of endocrine therapy on vaginal microbiome Methods: This single-center prospective cohort at Women's Hospital, Zhejiang University School of Medicine, will enroll 110 premenopausal women (18-45 years) with hormone receptor-positive breast cancer, allocated to OFS + AI or OFS + TAM based on clinical regimens. Vaginal swabs collected at baseline and 1, 3, 6, 12 months undergo 16S rRNA sequencing (V3-V4 region) with DADA2-based ASV analysis via QIIME 2 for species-level resolution. Assessments include Vaginal Health Index (VHI), GSM symptoms (VAS for dryness, dyspareunia, burning), s, and urinary symptoms (ICIQ-SF). Primary outcomes: microbiome diversity (Simpson index) and Lactobacillus abundance. Secondary: VHI, VAS, urinary scores. Analyses use repeated measures ANOVA and generalized estimating equations; sample size accounts for medium effect ( Conclusion: As a longitudinal study on vaginal microecology in this population, this protocol integrates molecular and clinical data to reveal GSM mechanisms, informing personalized interventions for better quality of life and adherence. Clinical trial registration: http://www.chictr.org.cn/showproj.html?proj=296570, Identifier (No. ChiCTR2500115283).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.